PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27306340-2	2016	The objective of this study was to investigate the effects of SD-208, TGF-beta-RI kinase inhibitor, on the expression of some miRNAs including a miR-17/92 cluster in retinoblastoma cells.	SD-208	62-68	miR-17-92a-1 cluster host gene	Homo sapiens	145-154
27464628-0	2016	[Effects of transforming growth factor beta1 receptor inhibitor SD-208 on human hypertrophic scar].	SD-208	64-70	transforming growth factor beta 1	Homo sapiens	12-44
27464628-1	2016	OBJECTIVE: To investigate the effects of transforming growth factor beta1 (TGF-beta1) receptor inhibitor SD-208 on human hypertrophic scar and its mechanisms.	SD-208	105-111	transforming growth factor beta 1	Homo sapiens	41-73
27464628-1	2016	OBJECTIVE: To investigate the effects of transforming growth factor beta1 (TGF-beta1) receptor inhibitor SD-208 on human hypertrophic scar and its mechanisms.	SD-208	105-111	transforming growth factor beta 1	Homo sapiens	75-84
27464628-25	2016	CONCLUSIONS: SD-208 has significant inhibition effect on human hypertrophic scars, and the mechanism is correlated to the inhibition of protein expression of endogenous TGF-beta1.	SD-208	13-19	transforming growth factor beta 1	Homo sapiens	169-178
25333263-5	2014	SD-208, a TGF-beta receptor 1 specific inhibitor, blocks this TGF-beta induced biology.	SD-208	0-6	transforming growth factor beta 1	Homo sapiens	10-18
27383203-11	2016	Inhibition of TGF-beta-Smad2/3 signaling with SD-208 significantly attenuated the upregulation of miRNA-181b.	SD-208	46-52	transforming growth factor beta 1	Homo sapiens	14-22
27383203-11	2016	Inhibition of TGF-beta-Smad2/3 signaling with SD-208 significantly attenuated the upregulation of miRNA-181b.	SD-208	46-52	SMAD family member 3	Homo sapiens	23-30
25747583-0	2015	SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest.	SD-208	0-6	protein kinase D1	Homo sapiens	16-32
25747583-3	2015	In this study, we describe the discovery of a novel PKD small molecule inhibitor, SD-208, from a targeted kinase inhibitor library screen, and the synthesis of a series of analogs to probe the structure-activity relationship (SAR) vs. PKD1.	SD-208	82-88	protein kinase D1	Homo sapiens	52-55
25747583-3	2015	In this study, we describe the discovery of a novel PKD small molecule inhibitor, SD-208, from a targeted kinase inhibitor library screen, and the synthesis of a series of analogs to probe the structure-activity relationship (SAR) vs. PKD1.	SD-208	82-88	polycystin 1, transient receptor potential channel interacting	Homo sapiens	235-239
25747583-4	2015	SD-208 displayed a narrow SAR profile, was an ATP-competitive pan-PKD inhibitor with low nanomolar potency and was cell active.	SD-208	0-6	protein kinase D1	Homo sapiens	66-69
25747583-5	2015	Targeted inhibition of PKD by SD-208 resulted in potent inhibition of cell proliferation, an effect that could be reversed by overexpressed PKD1 or PKD3.	SD-208	30-36	protein kinase D1	Homo sapiens	23-26
25747583-5	2015	Targeted inhibition of PKD by SD-208 resulted in potent inhibition of cell proliferation, an effect that could be reversed by overexpressed PKD1 or PKD3.	SD-208	30-36	polycystin 1, transient receptor potential channel interacting	Homo sapiens	140-144
25747583-5	2015	Targeted inhibition of PKD by SD-208 resulted in potent inhibition of cell proliferation, an effect that could be reversed by overexpressed PKD1 or PKD3.	SD-208	30-36	PKD3	Homo sapiens	148-152
25747583-7	2015	Mechanistically, SD-208-induced G2/M arrest was accompanied by an increase in levels of p21 in DU145 and PC3 cells as well as elevated phosphorylation of Cdc2 and Cdc25C in DU145 cells.	SD-208	17-23	H3 histone pseudogene 16	Homo sapiens	88-91
25747583-7	2015	Mechanistically, SD-208-induced G2/M arrest was accompanied by an increase in levels of p21 in DU145 and PC3 cells as well as elevated phosphorylation of Cdc2 and Cdc25C in DU145 cells.	SD-208	17-23	proprotein convertase subtilisin/kexin type 1	Homo sapiens	105-108
25747583-7	2015	Mechanistically, SD-208-induced G2/M arrest was accompanied by an increase in levels of p21 in DU145 and PC3 cells as well as elevated phosphorylation of Cdc2 and Cdc25C in DU145 cells.	SD-208	17-23	cyclin dependent kinase 1	Homo sapiens	154-158
25747583-7	2015	Mechanistically, SD-208-induced G2/M arrest was accompanied by an increase in levels of p21 in DU145 and PC3 cells as well as elevated phosphorylation of Cdc2 and Cdc25C in DU145 cells.	SD-208	17-23	cell division cycle 25C	Homo sapiens	163-169
25747583-8	2015	Most importantly, SD-208 given orally for 24 days significantly abrogated the growth of PC3 subcutaneous tumor xenografts in nude mice, which was accompanied by reduced proliferation and increased apoptosis and decreased expression of PKD biomarkers including survivin and Bcl-xL.	SD-208	18-24	proprotein convertase subtilisin/kexin type 1	Mus musculus	88-91
25747583-8	2015	Most importantly, SD-208 given orally for 24 days significantly abrogated the growth of PC3 subcutaneous tumor xenografts in nude mice, which was accompanied by reduced proliferation and increased apoptosis and decreased expression of PKD biomarkers including survivin and Bcl-xL.	SD-208	18-24	protein kinase D1	Mus musculus	235-238
25747583-8	2015	Most importantly, SD-208 given orally for 24 days significantly abrogated the growth of PC3 subcutaneous tumor xenografts in nude mice, which was accompanied by reduced proliferation and increased apoptosis and decreased expression of PKD biomarkers including survivin and Bcl-xL.	SD-208	18-24	baculoviral IAP repeat-containing 5	Mus musculus	260-268
25747583-8	2015	Most importantly, SD-208 given orally for 24 days significantly abrogated the growth of PC3 subcutaneous tumor xenografts in nude mice, which was accompanied by reduced proliferation and increased apoptosis and decreased expression of PKD biomarkers including survivin and Bcl-xL.	SD-208	18-24	BCL2-like 1	Mus musculus	273-279
25747583-9	2015	Our study has identified SD-208 as a novel efficacious PKD small molecule inhibitor, demonstrating the therapeutic potential of targeted inhibition of PKD for prostate cancer treatment.	SD-208	25-31	protein kinase D1	Homo sapiens	55-58
25747583-9	2015	Our study has identified SD-208 as a novel efficacious PKD small molecule inhibitor, demonstrating the therapeutic potential of targeted inhibition of PKD for prostate cancer treatment.	SD-208	25-31	protein kinase D1	Homo sapiens	151-154
26523217-0	2015	Down-regulation of miR-135b in colon adenocarcinoma induced by a TGF-beta receptor I kinase inhibitor (SD-208).	SD-208	103-109	microRNA 135b	Homo sapiens	19-27
26523217-0	2015	Down-regulation of miR-135b in colon adenocarcinoma induced by a TGF-beta receptor I kinase inhibitor (SD-208).	SD-208	103-109	transforming growth factor beta 1	Homo sapiens	65-73
26523217-11	2015	Our in silico study also predicted that SD-208 could modulate the expression of potential downstream tumor suppressor targets of the miR135b.	SD-208	40-46	microRNA 135b	Homo sapiens	133-140
26523217-12	2015	CONCLUSION: Our data provide novel evidence that anticancer effects of SD-208 (and likely other TGF-beta inhibitors) may be owing to their ability to regulate miRNAs expression.	SD-208	71-77	transforming growth factor beta 1	Homo sapiens	96-104
25982816-2	2015	Our study reveals that the TGFBR1 inhibitor SD208 effectively reduces prostate cancer bone metastases.	SD-208	44-49	transforming growth factor beta receptor 1	Homo sapiens	27-33
25333263-5	2014	SD-208, a TGF-beta receptor 1 specific inhibitor, blocks this TGF-beta induced biology.	SD-208	0-6	transforming growth factor beta 1	Homo sapiens	62-70
24515103-7	2014	Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles.	SD-208	270-275	transforming growth factor, beta 1	Mus musculus	55-63
24758301-8	2014	Treatment with a TGF-beta type I receptor kinase inhibitor, SD208, recovered AGE3-induced decreases in osterix (P < .001) and osteocalcin (P < .05) and antagonized the AGE3-induced increase in Runx2 mRNA expression in ST2 cells (P < .001).	SD-208	60-65	transforming growth factor beta 1	Homo sapiens	17-25
24758301-8	2014	Treatment with a TGF-beta type I receptor kinase inhibitor, SD208, recovered AGE3-induced decreases in osterix (P < .001) and osteocalcin (P < .05) and antagonized the AGE3-induced increase in Runx2 mRNA expression in ST2 cells (P < .001).	SD-208	60-65	RUNX family transcription factor 2	Homo sapiens	199-204
24685405-8	2014	SD-208 also abolished the promoting effect of TGF-beta on SMLC proliferation and migration but did not affect TGF-beta inhibition of VSMCs in vitro.	SD-208	0-6	transforming growth factor, beta 1	Mus musculus	46-54
24685405-9	2014	CTGF, a protein downstream of TGF-beta, was downregulated with the inhibition of Smad3 phosphorylation by SD-208, both in vitro and in vivo.	SD-208	106-112	cellular communication network factor 2	Mus musculus	0-4
24685405-9	2014	CTGF, a protein downstream of TGF-beta, was downregulated with the inhibition of Smad3 phosphorylation by SD-208, both in vitro and in vivo.	SD-208	106-112	transforming growth factor, beta 1	Mus musculus	30-38
24685405-9	2014	CTGF, a protein downstream of TGF-beta, was downregulated with the inhibition of Smad3 phosphorylation by SD-208, both in vitro and in vivo.	SD-208	106-112	SMAD family member 3	Mus musculus	81-86
24515103-7	2014	Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles.	SD-208	270-275	CREB regulated transcription coactivator 1	Mus musculus	185-191
24368833-6	2014	SD-208, a TGF-beta-receptor-I (TGF-beta-RI) kinase blocker, inhibited p-MyoFb differentiation as shown by stress fibre absence, low alpha-SMA expression, and high proliferation levels.	SD-208	0-6	actin gamma 2, smooth muscle	Rattus norvegicus	132-141
24425124-6	2014	The effects of GMH and SD208 on the TGF-beta pathway were evaluated by Western blot at day 3.	SD-208	23-28	transforming growth factor, beta 1	Rattus norvegicus	36-44
24425124-14	2014	SD208 inhibits GMH-induced activation of the TGF-beta pathway and leads to an improved developmental profile, partial recovery of cognitive and motor functions, and attenuation of GMH-induced brain atrophy and hydrocephalus.	SD-208	0-5	transforming growth factor, beta 1	Rattus norvegicus	45-53
22268139-10	2012	A 30-minute pretreatment of SD 208, a TGF-beta receptor-1 kinase inhibitor, prevented Ca(2+) waves from being evoked by TGF-beta.	SD-208	28-34	transforming growth factor beta 1	Homo sapiens	38-46
24305807-5	2013	The blockade of TGF-beta receptors by the TGFbetaRI antagonist SD-208 robustly suppressed bone cancer-induced thermal hyperalgesia on post-tumor day 14 (PTD 14).	SD-208	63-69	transforming growth factor, beta 1	Rattus norvegicus	16-24
23703870-9	2013	As an in vivo proof of principle, we demonstrate that administration of the TGF-beta receptor 1 (TbetaRI) kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture nonunion in Nf1(flox/-) ;Col2.3Cre mice.	SD-208	124-130	neurofibromin 1	Mus musculus	202-205
23703870-9	2013	As an in vivo proof of principle, we demonstrate that administration of the TGF-beta receptor 1 (TbetaRI) kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture nonunion in Nf1(flox/-) ;Col2.3Cre mice.	SD-208	124-130	collagen, type II, alpha 1	Mus musculus	215-219
23725749-7	2013	Moreover, hypoxia induced the phosphorylation of Smad2 and additional treatment with SD-208, an inhibitor of the TGF-beta receptor I kinase, resulted in a dose-dependent downregulation of CD133 and Oct4 in the K562/DOX cells.	SD-208	85-91	SMAD family member 2	Homo sapiens	49-54
23725749-7	2013	Moreover, hypoxia induced the phosphorylation of Smad2 and additional treatment with SD-208, an inhibitor of the TGF-beta receptor I kinase, resulted in a dose-dependent downregulation of CD133 and Oct4 in the K562/DOX cells.	SD-208	85-91	transforming growth factor beta 1	Homo sapiens	113-121
23725749-7	2013	Moreover, hypoxia induced the phosphorylation of Smad2 and additional treatment with SD-208, an inhibitor of the TGF-beta receptor I kinase, resulted in a dose-dependent downregulation of CD133 and Oct4 in the K562/DOX cells.	SD-208	85-91	prominin 1	Homo sapiens	188-193
23725749-7	2013	Moreover, hypoxia induced the phosphorylation of Smad2 and additional treatment with SD-208, an inhibitor of the TGF-beta receptor I kinase, resulted in a dose-dependent downregulation of CD133 and Oct4 in the K562/DOX cells.	SD-208	85-91	POU class 5 homeobox 1	Homo sapiens	198-202
22985514-4	2012	The TGF-beta 1 receptor kinase inhibitor SD208 enhances microglial proliferation by IL-34 and suppresses the neuroprotective effect of IL-34-treated microglia.	SD-208	41-46	transforming growth factor beta 1	Homo sapiens	4-12
22985514-4	2012	The TGF-beta 1 receptor kinase inhibitor SD208 enhances microglial proliferation by IL-34 and suppresses the neuroprotective effect of IL-34-treated microglia.	SD-208	41-46	interleukin 34	Homo sapiens	84-89
22985514-4	2012	The TGF-beta 1 receptor kinase inhibitor SD208 enhances microglial proliferation by IL-34 and suppresses the neuroprotective effect of IL-34-treated microglia.	SD-208	41-46	interleukin 34	Homo sapiens	135-140
22542888-4	2012	We found that treatment of pulmonary artery smooth muscle cells with TGF-beta1 significantly increased the expression of 15-LO and levels of 15-hydroxyeicosatetraenoic acid, product of 15-LO, which were inhibited by transforming growth factor-beta receptor I (TGFbetaRI) inhibitor, SD-208 and siRNA targeted to knockdown rat TGFbetaRI.	SD-208	282-288	transforming growth factor, beta 1	Rattus norvegicus	69-78
22542888-4	2012	We found that treatment of pulmonary artery smooth muscle cells with TGF-beta1 significantly increased the expression of 15-LO and levels of 15-hydroxyeicosatetraenoic acid, product of 15-LO, which were inhibited by transforming growth factor-beta receptor I (TGFbetaRI) inhibitor, SD-208 and siRNA targeted to knockdown rat TGFbetaRI.	SD-208	282-288	transforming growth factor, beta receptor 1	Rattus norvegicus	216-258
22268139-10	2012	A 30-minute pretreatment of SD 208, a TGF-beta receptor-1 kinase inhibitor, prevented Ca(2+) waves from being evoked by TGF-beta.	SD-208	28-34	transforming growth factor beta 1	Homo sapiens	120-128
21692070-8	2011	This effect was proportional to the total levels of TGF-beta1 and TGF-beta2 and was blocked by SB-431542 and SD-208, TGF-beta receptor I inhibitors.	SD-208	109-115	transforming growth factor beta 1	Homo sapiens	52-61
22844446-9	2012	SD208, a potent TGFbeta Receptor 1 (TGFbetaR1) kinase inhibitor, can efficiently block TGFbeta1/Smad signaling and attenuate EMT induction.	SD-208	0-5	transforming growth factor beta 1	Homo sapiens	87-95
21692070-8	2011	This effect was proportional to the total levels of TGF-beta1 and TGF-beta2 and was blocked by SB-431542 and SD-208, TGF-beta receptor I inhibitors.	SD-208	109-115	transforming growth factor beta 2	Homo sapiens	66-75
21692070-8	2011	This effect was proportional to the total levels of TGF-beta1 and TGF-beta2 and was blocked by SB-431542 and SD-208, TGF-beta receptor I inhibitors.	SD-208	109-115	transforming growth factor beta 1	Homo sapiens	52-60
21880834-6	2011	Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER.	SD-208	96-101	transforming growth factor beta 1	Homo sapiens	54-64
21880834-6	2011	Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER.	SD-208	96-101	chorionic somatomammotropin hormone 1	Homo sapiens	116-128
21465486-4	2011	Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis.	SD-208	107-113	transforming growth factor beta 1	Homo sapiens	55-63
21465486-4	2011	Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis.	SD-208	107-113	transforming growth factor beta receptor 1	Homo sapiens	64-68
21465486-4	2011	Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis.	SD-208	107-113	transforming growth factor beta receptor 1	Homo sapiens	91-95
21084275-0	2011	TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.	SD-208	29-35	transforming growth factor, beta 1	Mus musculus	0-8
21084275-4	2011	In this study, we tested the effect of a small molecule inhibitor of TGF-beta receptor I kinase (TbetaRI), SD-208, on various parameters affecting the development and progression of melanoma, both in vitro and in a mouse model of human melanoma bone metastasis.	SD-208	107-113	transforming growth factor, beta receptor I	Mus musculus	69-95
21084275-4	2011	In this study, we tested the effect of a small molecule inhibitor of TGF-beta receptor I kinase (TbetaRI), SD-208, on various parameters affecting the development and progression of melanoma, both in vitro and in a mouse model of human melanoma bone metastasis.	SD-208	107-113	transforming growth factor, beta receptor I	Mus musculus	97-104
18653707-6	2008	SD-208 treatment after MI resulted in a trend for reduced ventricular and renal gene expression of TGF-beta-activated kinase-1 (a downstream modulator of TGF-beta signaling) and a significant decrease in collagen 1, in association with a marked decrease in cardiac mass.	SD-208	0-6	mitogen-activated protein kinase kinase kinase 7	Mus musculus	99-126
20858897-7	2010	Furthermore, inhibition of TGFbeta signaling by TGFbeta receptor I inhibitor SD208 significantly reduced tumor area in K14cre/R26SmoM2 mice.	SD-208	77-82	transforming growth factor, beta 1	Mus musculus	27-34
20858897-7	2010	Furthermore, inhibition of TGFbeta signaling by TGFbeta receptor I inhibitor SD208 significantly reduced tumor area in K14cre/R26SmoM2 mice.	SD-208	77-82	transforming growth factor, beta 1	Mus musculus	48-55
18202349-5	2008	METHODS: We have used an orally active small-molecule TGF-beta receptor I inhibitor, SD-208, to determine the functional role of this pathway in MCT-PH.	SD-208	85-91	transforming growth factor beta 1	Homo sapiens	54-62
18474728-5	2008	Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-beta-mediated gene activation in BM stromal cells, and reverses TGF-beta-mediated cell-cycle arrest in BM CD34(+) cells.	SD-208	78-84	SMAD family member 2	Mus musculus	95-100
18474728-5	2008	Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-beta-mediated gene activation in BM stromal cells, and reverses TGF-beta-mediated cell-cycle arrest in BM CD34(+) cells.	SD-208	78-84	transforming growth factor, beta 1	Mus musculus	153-161
18474728-5	2008	Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-beta-mediated gene activation in BM stromal cells, and reverses TGF-beta-mediated cell-cycle arrest in BM CD34(+) cells.	SD-208	78-84	transforming growth factor, beta 1	Mus musculus	221-229
18474728-5	2008	Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-beta-mediated gene activation in BM stromal cells, and reverses TGF-beta-mediated cell-cycle arrest in BM CD34(+) cells.	SD-208	78-84	CD34 antigen	Mus musculus	263-267
18474728-6	2008	Furthermore, SD-208 treatment alleviates anemia and stimulates hematopoiesis in vivo in a novel murine model of bone marrow failure generated by constitutive hepatic expression of TGF-beta1.	SD-208	13-19	transforming growth factor, beta 1	Mus musculus	180-189
18202349-9	2008	Inhibition of TGF-beta signaling with SD-208 in established MCT-PH resulted in a small but significant improvement in hemodynamic parameters and medial remodeling.	SD-208	38-44	transforming growth factor beta 1	Homo sapiens	14-22
18202349-7	2008	Inhibition of TGF-beta signaling with SD-208 significantly attenuated the development of the PH and reduced pulmonary vascular remodeling.	SD-208	38-44	transforming growth factor beta 1	Homo sapiens	14-22
17381068-7	2006	rhTGFbeta1/rhTGFbeta3 induced ALK6 up-regulation was inhibited by SD-208, a TGFbeta type I receptor inhibitor.	SD-208	66-72	bone morphogenetic protein receptor type 1B	Homo sapiens	30-34
18229422-3	2007	Previously, we reported that treatment of pancreatic cancer cells in vitro with SD-208, a small molecule inhibitor of the TGF-beta receptor I kinase (TGF-betaRI), inhibited expression of genes associated with tumor progression and inhibited invasiveness in a cell-based assay.	SD-208	80-86	transforming growth factor beta receptor 1	Homo sapiens	122-148
18229422-3	2007	Previously, we reported that treatment of pancreatic cancer cells in vitro with SD-208, a small molecule inhibitor of the TGF-beta receptor I kinase (TGF-betaRI), inhibited expression of genes associated with tumor progression and inhibited invasiveness in a cell-based assay.	SD-208	80-86	transforming growth factor beta receptor 1	Homo sapiens	150-160
17400764-3	2007	In the present study, SD-208, a 2,4-disubstituted pteridine, ATP-competitive inhibitor of the TGFbeta receptor I kinase (TGFbetaRI), was used to inhibit cellular activities and tumor progression of PANC-1, a human pancreatic tumor line.	SD-208	22-28	transforming growth factor beta 1	Homo sapiens	94-101
17400764-7	2007	Using a Boyden chamber motility assay, we demonstrated that SD-208 inhibited TGFbeta-stimulated invasion in vitro.	SD-208	60-66	transforming growth factor beta 1	Homo sapiens	77-84
17381068-10	2006	The rhGDF5 stimulated SMAD1/5/8 phosphorylation was enhanced by rhTGFbetal/rhTGFbeta3 but inhibited by SD-208.	SD-208	103-109	SMAD family member 1	Homo sapiens	22-29
16888081-2	2006	We used an inhibitor of TGF-beta receptor I (TGF-betaRI) kinase, SD-208 (2,4-disubstituted pteridine, a ATP-competitive inhibitor of TGF-betaRI kinase), to determine the role of TGF-beta in airway allergic inflammation and remodeling.	SD-208	65-71	transforming growth factor, beta 1	Rattus norvegicus	24-32
16575856-1	2006	OBJECTIVE: To use a specific transforming growth factor beta receptor type I (TGFbetaRI; activin receptor-like kinase 5 [ALK-5]) kinase inhibitor (SD208) to determine the role of activation of the TGFbetaRI kinase (ALK-5) in maintaining the profibrotic phenotype of dermal fibroblasts in systemic sclerosis (SSc).	SD-208	147-152	transforming growth factor beta receptor 1	Homo sapiens	29-119
16707625-4	2006	We demonstrated that SD-208, but not SD-282, inhibited TGFbeta-induced SMAD signaling, myofibroblast transformation, and collagen gel contraction.	SD-208	21-27	transforming growth factor beta 1	Homo sapiens	55-62
16575856-1	2006	OBJECTIVE: To use a specific transforming growth factor beta receptor type I (TGFbetaRI; activin receptor-like kinase 5 [ALK-5]) kinase inhibitor (SD208) to determine the role of activation of the TGFbetaRI kinase (ALK-5) in maintaining the profibrotic phenotype of dermal fibroblasts in systemic sclerosis (SSc).	SD-208	147-152	transforming growth factor beta receptor 1	Homo sapiens	78-87
15708853-5	2005	Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon TbetaRI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGFbeta together with increased levels of wild type TbetaRII.	SD-208	28-34	transforming growth factor, beta receptor I	Mus musculus	128-132
15708853-5	2005	Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon TbetaRI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGFbeta together with increased levels of wild type TbetaRII.	SD-208	28-34	transforming growth factor, beta 1	Mus musculus	219-226
15708853-5	2005	Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon TbetaRI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGFbeta together with increased levels of wild type TbetaRII.	SD-208	28-34	transforming growth factor, beta receptor II	Mus musculus	271-279
15569984-6	2004	RESULTS: SD-208 significantly inhibits not only transcription but also secretion of both IL-6 and VEGF from BMSCs triggered by either TGF-beta1 or adhesion of MM cells to BMSCs.	SD-208	9-15	transforming growth factor beta 1	Homo sapiens	134-143
35050457-14	2022	Compared to the 10 nM DHT + 5 pM E2 group, the expressions of collagen I and fibronectin were decreased; the expression of elastin was increased in WPMY-1 cells after the supplement of TGF-beta/Smad pathway inhibitor SD208 group (p < 0.05, p < 0.01).	SD-208	217-222	elastin	Homo sapiens	123-130
15569984-3	2004	We show here that the TGF-beta receptor I kinase inhibitor SD-208 significantly decreases secretion of both IL-6 and vascular endothelial growth factor (VEGF) from BMSCs, as well as tumor cell growth triggered by MM cell adhesion to BMSCs.	SD-208	59-65	interleukin 6	Homo sapiens	108-112
15569984-3	2004	We show here that the TGF-beta receptor I kinase inhibitor SD-208 significantly decreases secretion of both IL-6 and vascular endothelial growth factor (VEGF) from BMSCs, as well as tumor cell growth triggered by MM cell adhesion to BMSCs.	SD-208	59-65	vascular endothelial growth factor A	Homo sapiens	117-151
15569984-3	2004	We show here that the TGF-beta receptor I kinase inhibitor SD-208 significantly decreases secretion of both IL-6 and vascular endothelial growth factor (VEGF) from BMSCs, as well as tumor cell growth triggered by MM cell adhesion to BMSCs.	SD-208	59-65	vascular endothelial growth factor A	Homo sapiens	153-157
15569984-5	2004	Effects of SD-208 on TGF-beta1-induced signaling pathways triggering IL-6 and VEGF transcription in BMSCs were also delineated.	SD-208	11-17	transforming growth factor beta 1	Homo sapiens	21-30
15569984-5	2004	Effects of SD-208 on TGF-beta1-induced signaling pathways triggering IL-6 and VEGF transcription in BMSCs were also delineated.	SD-208	11-17	interleukin 6	Homo sapiens	69-73
15569984-6	2004	RESULTS: SD-208 significantly inhibits not only transcription but also secretion of both IL-6 and VEGF from BMSCs triggered by either TGF-beta1 or adhesion of MM cells to BMSCs.	SD-208	9-15	interleukin 6	Homo sapiens	89-93
15569984-6	2004	RESULTS: SD-208 significantly inhibits not only transcription but also secretion of both IL-6 and VEGF from BMSCs triggered by either TGF-beta1 or adhesion of MM cells to BMSCs.	SD-208	9-15	vascular endothelial growth factor A	Homo sapiens	98-102
15520202-2	2004	Here we characterize the effects of a novel TGF-beta receptor (TGF-betaR) I kinase inhibitor, SD-208, on the growth and immunogenicity of murine SMA-560 and human LN-308 glioma cells in vitro and the growth of and immune response to intracranial SMA-560 gliomas in syngeneic VM/Dk mice in vivo.	SD-208	94-100	transforming growth factor beta 1	Homo sapiens	44-52
15520202-5	2004	Peripheral blood lymphocytes or purified T cells, cocultured with TGF-beta-releasing LN-308 glioma cells in the presence of SD-208, exhibit enhanced lytic activity against LN-308 targets.	SD-208	124-130	transforming growth factor beta 1	Homo sapiens	66-74
15520202-7	2004	SD-208 restores the lytic activity of polyclonal natural killer cells against glioma cells in the presence of recombinant TGF-beta or of TGF-beta-containing glioma cell supernatant.	SD-208	0-6	transforming growth factor beta 1	Homo sapiens	122-130
15520202-7	2004	SD-208 restores the lytic activity of polyclonal natural killer cells against glioma cells in the presence of recombinant TGF-beta or of TGF-beta-containing glioma cell supernatant.	SD-208	0-6	transforming growth factor beta 1	Homo sapiens	137-145
15520202-8	2004	The oral bioavailability of SD-208 was verified by demonstrating the inhibition of TGF-beta-induced Smad phosphorylation in spleen and brain.	SD-208	28-34	transforming growth factor beta 1	Homo sapiens	83-91
15520202-12	2004	These data define TGF-beta receptor I kinase inhibitors such as SD-208 as promising novel agents for the treatment of human malignant glioma and other conditions associated with pathological TGF-beta activity.	SD-208	64-70	transforming growth factor beta 1	Homo sapiens	18-26
15520202-12	2004	These data define TGF-beta receptor I kinase inhibitors such as SD-208 as promising novel agents for the treatment of human malignant glioma and other conditions associated with pathological TGF-beta activity.	SD-208	64-70	transforming growth factor beta 1	Homo sapiens	191-199
34373217-6	2021	Importantly, inhibition of the TGF-beta signaling through ectopic expression of dominant-negative Tgfbr2 (Tgfbr2-DN) or treatment with Tgfbr1 inhibitor SD-208 consistently abrogated tumor metastasis in nude mouse allograft assays.	SD-208	152-158	transforming growth factor alpha	Mus musculus	31-39
34373217-6	2021	Importantly, inhibition of the TGF-beta signaling through ectopic expression of dominant-negative Tgfbr2 (Tgfbr2-DN) or treatment with Tgfbr1 inhibitor SD-208 consistently abrogated tumor metastasis in nude mouse allograft assays.	SD-208	152-158	transforming growth factor, beta receptor I	Mus musculus	135-141
34504485-9	2021	Pharmacological blockade of the TGF-beta signalling pathway with SD208 (TGF-beta receptor type I inhibitor), SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-beta-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen secretion.	SD-208	65-70	transforming growth factor alpha	Homo sapiens	32-40
34504485-9	2021	Pharmacological blockade of the TGF-beta signalling pathway with SD208 (TGF-beta receptor type I inhibitor), SIS3 (Smad3 inhibitor) or (5Z)-7-oxozeaenol (TGF-beta-activated kinase 1 inhibitor) ameliorated fibronectin levels and type I collagen secretion.	SD-208	65-70	fibronectin 1	Homo sapiens	205-216
35050457-14	2022	Compared to the 10 nM DHT + 5 pM E2 group, the expressions of collagen I and fibronectin were decreased; the expression of elastin was increased in WPMY-1 cells after the supplement of TGF-beta/Smad pathway inhibitor SD208 group (p < 0.05, p < 0.01).	SD-208	217-222	transforming growth factor alpha	Homo sapiens	185-193
35050457-14	2022	Compared to the 10 nM DHT + 5 pM E2 group, the expressions of collagen I and fibronectin were decreased; the expression of elastin was increased in WPMY-1 cells after the supplement of TGF-beta/Smad pathway inhibitor SD208 group (p < 0.05, p < 0.01).	SD-208	217-222	SMAD family member 7	Homo sapiens	194-198
33427061-3	2021	TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012).	SD-208	26-32	transforming growth factor beta 1	Homo sapiens	0-5
34013984-7	2021	This inhibitory effect of TGFbeta1 on healthy hematopoiesis was functionally corrobated and could be pharmacologically reverted by SD208, an inhibitor of TGFbeta receptor 1 signaling.	SD-208	131-136	transforming growth factor beta 1	Homo sapiens	26-34
33427061-3	2021	TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012).	SD-208	26-32	transforming growth factor beta 1	Homo sapiens	71-76
33427061-3	2021	TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012).	SD-208	26-32	platelet derived growth factor subunit B	Homo sapiens	96-101
33427061-3	2021	TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012).	SD-208	26-32	cellular communication network factor 2	Homo sapiens	102-106
33427061-8	2021	Remarkably, TGFB1 receptor antagonist SD-208 prevented all of these abnormalities excepting increased LPA2.	SD-208	38-44	transforming growth factor beta 1	Homo sapiens	12-17
33427061-8	2021	Remarkably, TGFB1 receptor antagonist SD-208 prevented all of these abnormalities excepting increased LPA2.	SD-208	38-44	lysophosphatidic acid receptor 2	Homo sapiens	102-106
33427061-9	2021	SD208 inhibits only one arm of LPA signaling: LPA2-Galphaq-alphavbeta6-integrin dependent production of active TGFB1 and its receptor-bound downstream effects.	SD-208	0-5	lysophosphatidic acid receptor 2	Homo sapiens	46-50
33427061-9	2021	SD208 inhibits only one arm of LPA signaling: LPA2-Galphaq-alphavbeta6-integrin dependent production of active TGFB1 and its receptor-bound downstream effects.	SD-208	0-5	transforming growth factor beta 1	Homo sapiens	111-116
33427061-12	2021	SD208 effects may also involve mitigation of injury caused by IRI-induced TGFB1 signaling in endothelial cells and monocytes.	SD-208	0-5	transforming growth factor beta 1	Homo sapiens	74-79
31829243-9	2019	RESULTS: TGFbeta-1 was induced in cultures expressing Nef at 24 h followed by CCL2 induction which was prevented by blocking TGFbetaRI with SD208 (competitive inhibitor).	SD-208	140-145	transforming growth factor, beta 1	Rattus norvegicus	9-18
32443848-6	2020	Fibrotic phenotype of cardiac microtissues was inhibited by treatment with TGF-beta-receptor type 1 inhibitor SD208 in a dose-dependent manner.	SD-208	110-115	transforming growth factor beta receptor 1	Homo sapiens	75-99
32317146-11	2021	Smad signal transduction activation was significantly down-regulated by Bindarit (300 muM) and/or SD208 (1 muM) with TGF-beta1 compared to vehicle control with TGF-beta1.	SD-208	98-103	transforming growth factor beta 1	Homo sapiens	117-126
32317146-11	2021	Smad signal transduction activation was significantly down-regulated by Bindarit (300 muM) and/or SD208 (1 muM) with TGF-beta1 compared to vehicle control with TGF-beta1.	SD-208	98-103	transforming growth factor beta 1	Homo sapiens	160-169
32303620-9	2020	Blockade of TGF-beta-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-beta, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model.	SD-208	75-81	CD8a molecule	Homo sapiens	102-105
32303620-9	2020	Blockade of TGF-beta-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-beta, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model.	SD-208	75-81	CD4 molecule	Homo sapiens	111-114
32303620-9	2020	Blockade of TGF-beta-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-beta, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model.	SD-208	75-81	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	116-120
32303620-9	2020	Blockade of TGF-beta-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-beta, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model.	SD-208	75-81	nuclear receptor subfamily 1 group I member 3	Homo sapiens	121-124
32303620-9	2020	Blockade of TGF-beta-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-beta, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model.	SD-208	75-81	transforming growth factor alpha	Homo sapiens	12-20
32303620-10	2020	Combination treatment with SD-208 also led to increased viability and lower expression of PD-1 on ROR1-CAR T-cells at the end of the antitumor response.	SD-208	27-33	MHC class I antigen 1	Sus scrofa	90-94
32303620-10	2020	Combination treatment with SD-208 also led to increased viability and lower expression of PD-1 on ROR1-CAR T-cells at the end of the antitumor response.	SD-208	27-33	receptor tyrosine kinase like orphan receptor 1	Sus scrofa	98-102
32303620-10	2020	Combination treatment with SD-208 also led to increased viability and lower expression of PD-1 on ROR1-CAR T-cells at the end of the antitumor response.	SD-208	27-33	CXADR Ig-like cell adhesion molecule	Sus scrofa	103-106
32303620-12	2020	Our study supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T-cells from TGF-beta, as exemplified by the TGF-beta-receptor kinase inhibitor SD-208 in this study.	SD-208	207-213	CXADR Ig-like cell adhesion molecule	Sus scrofa	123-126
32303620-12	2020	Our study supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T-cells from TGF-beta, as exemplified by the TGF-beta-receptor kinase inhibitor SD-208 in this study.	SD-208	207-213	transforming growth factor alpha	Sus scrofa	140-148
32303620-12	2020	Our study supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T-cells from TGF-beta, as exemplified by the TGF-beta-receptor kinase inhibitor SD-208 in this study.	SD-208	207-213	transforming growth factor alpha	Sus scrofa	172-180
31829243-9	2019	RESULTS: TGFbeta-1 was induced in cultures expressing Nef at 24 h followed by CCL2 induction which was prevented by blocking TGFbetaRI with SD208 (competitive inhibitor).	SD-208	140-145	C-C motif chemokine ligand 2	Rattus norvegicus	78-82
31829243-12	2019	Brain tissue from Nef-treated rats given SD208 showed reduced CCL2, phospho-SMAD2, cluster of differentiation 163 (CD163), and GFAP immunoreactivity compared to the placebo group.	SD-208	41-46	C-C motif chemokine ligand 2	Rattus norvegicus	62-66
31829243-12	2019	Brain tissue from Nef-treated rats given SD208 showed reduced CCL2, phospho-SMAD2, cluster of differentiation 163 (CD163), and GFAP immunoreactivity compared to the placebo group.	SD-208	41-46	SMAD family member 2	Rattus norvegicus	76-81
31829243-12	2019	Brain tissue from Nef-treated rats given SD208 showed reduced CCL2, phospho-SMAD2, cluster of differentiation 163 (CD163), and GFAP immunoreactivity compared to the placebo group.	SD-208	41-46	glial fibrillary acidic protein	Rattus norvegicus	127-131
31829243-14	2019	In contrast, rats treated with Nef + SD208 showed better spatial learning suggesting that Nef disrupts memory formation in a TGFbeta-1-dependent manner.	SD-208	37-42	transforming growth factor, beta 1	Rattus norvegicus	125-134
31442332-8	2019	We also discovered that SD-208 promoted osteoblastic differentiation (and overcame the TGFbeta-induced block in osteoblastogenesis) in myeloma patient bone marrow stromal cells in vitro, comparable to normal donors.	SD-208	24-30	transforming growth factor beta 1	Homo sapiens	87-94
29773599-6	2018	These suppressive effects of transforming growth factor beta1 on stromal cell functionality were abrogated by SD-208, an established inhibitor of transforming growth factor beta receptor signaling.	SD-208	110-116	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	56-61
31240740-6	2019	This sustained enhancement by TGF-beta1 could be blocked by extracellular treatment of selective TGF-beta receptor I antagonist SD-208, and abolished by blockade of intracellular several non-Smad-signaling pathways.	SD-208	128-134	transforming growth factor, beta 1	Rattus norvegicus	30-39
29773599-8	2018	Our findings establish transforming growth factor beta1 as a relevant trigger causing functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia and identify SD-208 as a candidate to revert these effects.	SD-208	206-212	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	50-55
28229177-7	2017	To block TGF-beta signaling, we used SD208, a TGF-beta type I receptor kinase inhibitor.	SD-208	37-42	transforming growth factor, beta 1	Mus musculus	9-17
28229177-7	2017	To block TGF-beta signaling, we used SD208, a TGF-beta type I receptor kinase inhibitor.	SD-208	37-42	transforming growth factor, beta 1	Mus musculus	46-54